secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001193125-24-090821
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics appoints Dr. Lori Kunkel to Board of Directors
-------------------------------------------------------------------

- Dr. Kunkel appointed as Class III director, term expiring at 2026 annual meeting.
- Annual cash retainer of $35,000; stock option grant with fair value ~$500,000 vesting monthly over 3 years.
- No arrangements or transactions requiring disclosure under Item 404(a) of Reg S-K.
- Dr. Kunkel brings 25+ years oncology drug development experience; previously scientific advisor to Enliven.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312524090821/0001193125-24-090821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312524090821/d816494d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-090821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer